Published in Obesity and Diabetes Week, August 13th, 2007
The presentation summarized results from preclinical studies demonstrating that MSI-1436 is a potent, highly-selective and reversible inhibitor of PTP-1B, an enzyme central to the function of both the leptin and insulin pathways. The mechanism of this inhibition, as indicated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.